US 2011/0257091 A1 · INSULIN ANALOGS

Abstract

Full potency analogs of insulin are provided wherein the analog comprises a modification of the tyrosine residue at position 19 of the A chain.

Dependent claims

A polypeptide comprising the sequence GIVEQCCX1SICSLYQLENX2CX3 (SEQ ID NO:

3), wherein
X1 is selected from the group consisting of threonine and histidine;
X2 is an amino acid of the general structure
wherein R4 is NH2 or OCH3;
and
X3 is asparagine, glycine or alanine;
or an analog thereof comprising a sequence that differs from SEQ ID NO:
3 by 1 to 3 amino acid modifications, selected from positions A5, A8, A9, A10, A14, A15, A17, A18.

5 more elements

A single chain insulin analog comprises a compound of the formula:

B-P-A19, wherein:
B represents a sequence comprising a sequence of X4LCGX5X6LVEALYLVCG ERGFF (SEQ ID NO:
4);
A19 represents a sequence comprising a sequence of GIVEQCCX1SICSLYQLENX2CX3 (SEQ ID NO:
3);
and
P represents a peptide linker of about 4 to about 14 amino acids, further wherein
X1 is selected from the group consisting of threonine and histidine;
X2 is an amino acid of the general structure
wherein R4 is NH2 or OCH3;
X3 is asparagine or glycine;
X4 is selected from the group consisting of histidine and threonine;
X5 is selected from the group consisting of alanine, glycine and serine;
X6 is selected from the group consisting of histidine, aspartic acid, glutamic acid, homocysteic acid and cysteic acid.

11 more elements

Dependencies are inferred from the claim text.